Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasmsBenjamin H. Durham, Omar Abdel‐Wahab, Estibaliz Lopez Rodrigo et al.|Nature Medicine|2019Cited by 228
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaOla Landgren, Neha Korde, Sydney X. Lu et al.|JAMA Oncology|2021Cited by 119
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple MyelomaOla Landgren, Ingemar Turesson, Jonathan N. Hofmann et al.|JAMA Oncology|2019Cited by 97
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Ola Landgren, Neha Korde et al.|The Lancet Haematology|2021Cited by 95